Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Background While patients with cancer have traditionally received oncology treatments through intravenous (IV) administration, some therapies are becoming available via alternative modes of administration, such as subcutaneous (SC). This study aimed to evaluate IV versus SC therapy administration from the perspectives of the patient, healthcare provider (HCP), and healthcare system.Methods A systematic review was conducted, searching MEDLINE and Embase databases from 2000 to 2022. This was supplemented with grey literature searches of additional sources such as conference proceedings. Observational studies and clinical trials were included if they assessed adult patients with any cancer type who were treated with pharmacologic therapies administered via IV or SC and included patient- or HCP-reported outcomes or healthcare system perspectives on the mode of administration. Records identified by the literature search were screened by two independent reviewers. Included studies were data extracted by a single reviewer and validated by a second reviewer and synthesized using a narrative approach.Results After screening, 33 unique studies were included in the systematic review. Patients and HCPs reported substantially more favorable preference rates for SC over IV treatment. Additionally, from the patient perspective there were reductions in treatment time and economic burden for SC compared with IV therapy. From the HCP's perspective, treatment time was consistently reduced by SC compared with IV treatment administration. Although information on the impact of SC and IV treatments for oncology on healthcare systems was limited, the use of SC formulations showed consistent cost savings (direct costs) and time savings from this perspective considering various uptake scenarios compared with IV administration.Conclusion Compared with IV administration, SC oncology treatment is a preferred option by patients and HCPs, increasing optionality and reducing treatment time while simultaneously increasing capacity and reducing the financial burden on healthcare systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
Krohe, M., Eek, D., Mazar, I., Horsfield, A., Pompilus, F., Friebe, R., & Shields, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106629 · Cited by 265 · cited 1×
“While many cancer therapies are delivered through intravenous (IV) administration [1], over the past decade, novel therapies have increasingly been made available via alterna‑ tive modes of administration, such as subcu‑ taneous (SC) or intramuscular injections, and several existing treatments that…”
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230 · cited 2×
“In total, 12 studies (7 trials and 5 observational studies) were identified that reported patient preference data [11, 13, 17–20, 24, 31, 33, 35, 42, 43], 8 (5 trials and 3 observational studies) reported information related to patient satisfac‑ tion [18, 31, 34, 35, 39, 41, 43–45], 18 (16 obser‑…”
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu364 · Cited by 177 · cited 3×
“%) or from SC to IV (77.0–89.8%), and these propor‑ tions remained substantially higher for SC treat‑ ment than the proportions with a preference for IV treatment (8.9–15.6%; Table 1) [17, 24, 35, 49].”
InfluentialRummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154 · cited 4×
“%) or from SC to IV (77.0–89.8%), and these propor‑ tions remained substantially higher for SC treat‑ ment than the proportions with a preference for IV treatment (8.9–15.6%; Table 1) [17, 24, 35, 49].”
InfluentialDavies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu524 · Cited by 114 · cited 2×
“…14 included stud‑ ies (11 trials and t3hree observational studies) reported treatment‑related adverse/safety events and identified that injection site reactions were reported most frequently for SC treatments (e.g., pain, swelling, and erythema) [12, 17, 19, 21, 24, 33–37, 42, 43, 47, 50].”
De Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine · doi:10.1002/cam4.573 · Cited by 112 · cited 4×
“Mean reduction in total therapy time for SC compared with IV administration among studies that reported this measure was typically 2 h or more [14, 16, 22, 25–29, 34, 38, 43, 46].”
InfluentialSalar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade-Potelleret, F., Janikova, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2631 · Cited by 98 · cited 2×
“…14 included stud‑ ies (11 trials and t3hree observational studies) reported treatment‑related adverse/safety events and identified that injection site reactions were reported most frequently for SC treatments (e.g., pain, swelling, and erythema) [12, 17, 19, 21, 24, 33–37, 42, 43, 47, 50].”
O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.047 · Cited by 83
Lugtenburg, P., Avivi, I., Berenschot, H., Ilhan, O., Marolleau, J. P., Nagler, A., Rueda, A., Tani, M., Turgut, M., Osborne, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.173583 · Cited by 75 · cited 3×
“Mean reduction in total therapy time for SC compared with IV administration among studies that reported this measure was typically 2 h or more [14, 16, 22, 25–29, 34, 38, 43, 46].”
Pivot, X., Spano, J. P., Espie, M., Cottu, P., Jouannaud, C., Pottier, V., Moreau, L., Extra, J. M., Lortholary, A., Rivera, P., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.009 · Cited by 70 · cited 6×
“…details [14–16, 18, 19, 22, 23, 25–30, 33, 34, 38, 43, 46], 14 (11 trials and 3 observational studies) reported patient experi‑ ence data with respect to administration‑related reactions [12, 17, 19, 21, 24, 33–37, 41–43, 47], and 1 reported information about utilities or HRQoL [33, 48].”
InfluentialAnderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019) · Future Oncology · doi:10.2217/fon-2019-0368 · Cited by 69 · cited 2×
“A rapid review assessing the humanis‑ tic and economic impact of IV and SC admin‑ istration for cancer therapies over a 5‑year span demonstrated increased resource and cost savings with SC administration, as well as improved patient quality of life and patient preference for SC compared with IV [8].”
Subcutaneous administration of anticancer agents.
Levêque, D. (2014) · PubMed · Cited by 69
Usmani, S. Z., Nahi, H., Legiec, W. M., Grosicki, S., Vorobyev, V. I., Špıčka, I., Hungria, V., Korenkova, S., Bahlis, N. J., Flogegård, M., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.279459 · Cited by 68 · cited 1×
“…14 included stud‑ ies (11 trials and t3hree observational studies) reported treatment‑related adverse/safety events and identified that injection site reactions were reported most frequently for SC treatments (e.g., pain, swelling, and erythema) [12, 17, 19, 21, 24, 33–37, 42, 43, 47, 50].”
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66 · cited 1×
“Another systematic review of 71 studies published between 2012 and 2020 included patients who received oncology bio‑ logics in a hospital setting, assessing global data on cost as well as time and resource use [54].”
Rule, S., Collins, G. P., & Samanta, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914033 · Cited by 66 · cited 4×
“Mean reduction in total therapy time for SC compared with IV administration among studies that reported this measure was typically 2 h or more [14, 16, 22, 25–29, 34, 38, 43, 46].”
InfluentialBurcombe, R., Chan, S., Simcock, R., Samanta, K., Percival, F., & Barrett-Lee, P. (2013) · Advances in Breast Cancer Research · doi:10.4236/abcr.2013.24022 · Cited by 59 · cited 2×
“In particular, SC administration has been reported by several studies to be preferred over IV therapies by patients who are receiving oncology treatment [4–7].”
Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., & De la Haba-Rodríguez, J. (2017) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1684-4 · Cited by 54 · cited 1×
“…assessed HCP preference [11, 17, 18, 33], 3 studies (1 trial and 2 observational studies) that evaluated HCP satisfaction [20, 33, 39], and 21 studies (6 trials and 15 observational studies) that assessed time‑associated benefits to HCPs [4, 12, 14–16, 18, 19, 22–25, 27–30, 33–36, 38, 40, 46, 51].”
Assouline, S. E., Buccheri, V., Delmer, A. J., Gaïdano, G., Trněný, M., Berthillon, N., Brewster, M., Catalani, O., Li, S., McIntyre, C., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00004-1 · Cited by 50
Gligorov, J., Ataseven, B., Verrill, M. W., Laurentiis, M. D., Jung, K. H., Azim, H. A., Al-Sakaff, N. J. A., Lauer, S., Shing, M., Pivot, X. B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.010 · Cited by 50
Tjalma, W. A. A., Van den Mooter, T., Mertens, T., Bastiaens, V., Huizing, M. T., & Papadimitriou, K. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.12.006 · Cited by 46 · cited 4×
“Mean reduction in total therapy time for SC compared with IV administration among studies that reported this measure was typically 2 h or more [14, 16, 22, 25–29, 34, 38, 43, 46].”
InfluentialOlofsson, S., Norrlid, H., Karlsson, E., Wilking, U., & Ragnarson Tennvall, G. (2016) · The Breast · doi:10.1016/j.breast.2016.07.008 · Cited by 45 · cited 6×
“Indirect cost sav‑ ings were also observed for SC over IV adminis‑ tration in a subset of studies that reported these data, and were driven primarily by the differ‑ ential impact on patient and/or caregiver work productivity [14, 19, 25–27].”
InfluentialDenys, H. G., Martinez-Mena, C., Martens, M., D’hondt, R., Graas, M.-P., Evron, E., Fried, G., Ben-Baruch, N. E., Vulsteke, C., & Steenberghe, M. V. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05604-7 · Cited by 44 · cited 3×
“…14 included stud‑ ies (11 trials and t3hree observational studies) reported treatment‑related adverse/safety events and identified that injection site reactions were reported most frequently for SC treatments (e.g., pain, swelling, and erythema) [12, 17, 19, 21, 24, 33–37, 42, 43, 47, 50].”
Subcutaneous Versus Intravenous Bortezomib
Barbee, M. S., Harvey, R. D., Lonial, S., Kaufman, J. L., Wilson, N. M., McKibbin, T., Hutcherson, D. A., Surati, M. J., Valla, K., & Shah, K. S. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013503122 · Cited by 40
Mateos, M., & Miguel, J. F. S. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711432020 · Cited by 39
Hedayati, E., Fracheboud, L., Srikant, V., Greber, D., Wallberg, S., & Linder Stragliotto, C. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211783 · Cited by 39
Matza, L., Cong, Chung, Stopeck, A., Tonkin, K., Brown, Braun, Brunt, V., & McDaniel, K. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s44947 · Cited by 38
Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000648 · Cited by 37 · cited 2×
“…assessed HCP preference [11, 17, 18, 33], 3 studies (1 trial and 2 observational studies) that evaluated HCP satisfaction [20, 33, 39], and 21 studies (6 trials and 15 observational studies) that assessed time‑associated benefits to HCPs [4, 12, 14–16, 18, 19, 22–25, 27–30, 33–36, 38, 40, 46, 51].”
Harvey, M. J., Zhong, Y., Morris, E., Beverage, J. N., Epstein, R. S., & Chawla, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261336 · Cited by 36 · cited 3×
“Mean reduction in total therapy time for SC compared with IV administration among studies that reported this measure was typically 2 h or more [14, 16, 22, 25–29, 34, 38, 43, 46].”
Walzer, S., Ponzetti, C., Canciani, M., Farina, M., & Era, S. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s97319 · Cited by 35
Fallowfield, L., Osborne, S., Langridge, C., Monson, K., Kilkerr, J., & Jenkins, V. (2015) · The Breast · doi:10.1016/j.breast.2015.01.002 · Cited by 34 · cited 1×
“[ 18, 31, 39, 44].”
Usmani, S. Z., Mateos, M., Hungria, V., Iida, S., Bahlis, N. J., Nahi, H., Magen, H., Cavo, M., Hulin, C., White, D. J., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03365-w · Cited by 33 · cited 2×
“…details [14–16, 18, 19, 22, 23, 25–30, 33, 34, 38, 43, 46], 14 (11 trials and 3 observational studies) reported patient experi‑ ence data with respect to administration‑related reactions [12, 17, 19, 21, 24, 33–37, 41–43, 47], and 1 reported information about utilities or HRQoL [33, 48].”
O'Brien, G. L., O'Mahony, C., Cooke, K., Kinneally, A., Sinnott, S.-J., Walshe, V., Mulcahy, M., & Byrne, S. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.01.011 · Cited by 29 · cited 5×
“Indirect cost sav‑ ings were also observed for SC over IV adminis‑ tration in a subset of studies that reported these data, and were driven primarily by the differ‑ ential impact on patient and/or caregiver work productivity [14, 19, 25–27].”
InfluentialSwitching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
Gligorov, J., Curigliano, G., Müller, V., Knoop, A. S., Jenkins, V. A., Verma, S., Osborne, S., Lauer, S., Machackova, Z., Fallowfield, L. J., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.05.004 · Cited by 24 · cited 2×
“…14 included stud‑ ies (11 trials and t3hree observational studies) reported treatment‑related adverse/safety events and identified that injection site reactions were reported most frequently for SC treatments (e.g., pain, swelling, and erythema) [12, 17, 19, 21, 24, 33–37, 42, 43, 47, 50].”
Olsen, J., Jensen, K. F., Olesen, D. S., & Knoop, A. S. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0048 · Cited by 24 · cited 4×
“Mean reduction in total therapy time for SC compared with IV administration among studies that reported this measure was typically 2 h or more [14, 16, 22, 25–29, 34, 38, 43, 46].”
InfluentialSwitching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Mateos, M., Rigaudeau, S., Basu, S., Špıčka, I., Schots, R., Wróbel, T., Cook, G., Beksaç, M., Gries, K. S., Kudva, A., et al. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221103551 · Cited by 21 · cited 3×
“In total, 12 studies (7 trials and 5 observational studies) were identified that reported patient preference data [11, 13, 17–20, 24, 31, 33, 35, 42, 43], 8 (5 trials and 3 observational studies) reported information related to patient satisfac‑ tion [18, 31, 34, 35, 39, 41, 43–45], 18 (16 obser‑…”
Cebas, A. L., Cascajares, S. C., Bravo, S. P., Del Puy Goyache Goñi, M., Gonzalez Monterrubio, G., Cardenas, P., & Jm, F. P. (2017) · PubMed · Cited by 21
Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-017-3147-y · Cited by 20 · cited 9×
“Only one observational study reported HRQoL/utilities data [33, 48].”
InfluentialFarolfi, A., Silimbani, P., Gallegati, D., Petracci, E., Schirone, A., Altini, M., & Masini, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18527 · Cited by 19 · cited 3×
“Of the included studies, 13 assessed trastuzumab alone [11–23], 1 assessed trastuzumab combined with pertuzumab [24], 4 assessed trastuzumab and rituximab [25–28], 11 assessed rituximab alone [29–39], 3 assessed daratumumab alone [40–42], and 1 assessed bortezomib alone [43] (summarized in Supple‑…”
García‐Muñoz, R., Quero, C., Persona, E. P., Domingo‐García, A., Pérez‐López, C., Villaescusa‐de‐la‐Rosa, T., Martínez‐Castro, A. M., Arguiñano‐Pérez, J. M., Parra‐Cuadrado, J. F., & Panizo, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.16227 · Cited by 19 · cited 3×
“In total, 12 studies (7 trials and 5 observational studies) were identified that reported patient preference data [11, 13, 17–20, 24, 31, 33, 35, 42, 43], 8 (5 trials and 3 observational studies) reported information related to patient satisfac‑ tion [18, 31, 34, 35, 39, 41, 43–45], 18 (16 obser‑…”
Altini, M., Gentili, N., Balzi, W., Musuraca, G., Maltoni, R., Masini, C., Galardi, F., Bertoni, L., & Massa, I. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1764353 · Cited by 17
Pradelli, L., Massaia, M., Todisco, E., Gherlinzoni, F., Furlan, A., Latargia, M. L., Grande, E., Tripoli, E., Occhipinti, F., Comello, F., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6699 · Cited by 14
Ciruelos, E., Montaño, Á., Rodriguez, C. A., González‐Flores, E., Lluch, A. M., Garrigós, L., Quiroga, V., Antón, A., Malón, D., Chacón, J. I., et al. (2020) · European Journal of Cancer Care · doi:10.1111/ecc.13253 · Cited by 11 · cited 5×
“Of the 4 studies that assessed HCP preference, three were trastuzumab‑based studies for breast cancer that assessed HCP preference for treat‑ ment administration and consistently demon‑ strated a strong and preference for SC treatment (63.6–100%; Table 1) [11, 17, 18].”
InfluentialEvaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites
Stewart, D. A., Boudreault, J., Maturi, B., Boras, D., & Foley, R. (2018) · Current Oncology · doi:10.3747/co.25.4231 · Cited by 11 · cited 2×
“In patients with NHL, there were notable time savings when patients were treated with SC compared with IV rituximab of up to approxi‑ mately 171,000 h over 3 years [32].”
Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres
Stewart, D. A., Aucoin, J.-S., Crosbie, T., Forman, M., Lye, E., Christofides, A., & Mitha, A. (2020) · Current Oncology · doi:10.3747/co.27.6041 · Cited by 9 · cited 3×
“…and 2 trials) reported data relevant to patient‑perceived benefits including economic and/or time‑savings details [14–16, 18, 19, 22, 23, 25–30, 33, 34, 38, 43, 46], 14 (11 trials and 3 observational studies) reported patient experi‑ ence data with respect to administration‑related…”
Skalicky, A. M., Bennett, B. L., Raimbourg, J., Lonardi, S., Correll, J. R., Lugowska, I. A., Dixon, M., Sargalo, N., & Martin, M. L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1310546 · Cited by 8 · cited 1×
“These findings are generally consistent with those of studies that were pub‑ lished after the search date and thus were not included in the systematic review [52, 53].”
Dürig, J., Uhlig, J., Gerhardt, A., Ritter, M., Hapke, G., Heßling, J., Staib, P., Wolff, F., Krumm, K., & von Weikersthal, L. F. (2022) · Cancer Medicine · doi:10.1002/cam4.5160 · Cited by 6 · cited 6×
“…13, 17–20, 24, 31, 33, 35, 42, 43], 8 (5 trials and 3 observational studies) reported information related to patient satisfac‑ tion [18, 31, 34, 35, 39, 41, 43–45], 18 (16 obser‑ vational and 2 trials) reported data relevant to patient‑perceived benefits including economic and/or time‑savings…”
InfluentialFederici, C., Rognoni, C., Costa, F., Armeni, P., Crovato, E., & Bellucci, S. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.006 · Cited by 6 · cited 3×
“In a separate study of patients with mul‑ tiple myeloma who were treated with daratu‑ mumab, the total time saved per infusion for SC compared with IV administration ranged from 72.00 to 106.00 min [40].”
InfluentialValachis, A., Sundqvist, M., Carlsson, L. M. S., Li, B., Chiesa, F., Uhde, M., & Sanglier, T. (2019) · Future Oncology · doi:10.2217/fon-2019-0160 · Cited by 5 · cited 1×
“In total, 12 studies (7 trials and 5 observational studies) were identified that reported patient preference data [11, 13, 17–20, 24, 31, 33, 35, 42, 43], 8 (5 trials and 3 observational studies) reported information related to patient satisfac‑ tion [18, 31, 34, 35, 39, 41, 43–45], 18 (16 obser‑…”
Sazatornil, M. R. A., Arenaza, A., Bayo, J. L., Mata, J. G., de Castro, J. M. G., León, J., Letéllez-Fernández, J., Reguero, V., Chamorro, C. M., & Salar, A. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06277-8 · Cited by 5 · cited 8×
“Indirect cost sav‑ ings were also observed for SC over IV adminis‑ tration in a subset of studies that reported these data, and were driven primarily by the differ‑ ential impact on patient and/or caregiver work productivity [14, 19, 25–27].”
InfluentialPetrini, M., Gaïdano, G., Mengarelli, A., Consoli, U., Santoro, A., Liberati, A. M., Ladetto, M., Fraticelli, V. L., Guarini, A., Mannina, D., et al. (2022) · Advances in Hematology · doi:10.1155/2022/5581772 · Cited by 4
Wu, E., Schenkel, B., Povsic, M., Wyn, R., Hernani, M., & Kornalska, K. (2019) · Value in Health · doi:10.1016/j.jval.2019.04.239 · Cited by 1 · cited 1×
“Although no reimbursement submissions from HTA websites met the inclusion criteria of this review, it is clear that HTA bodies are approving the use of newer SC modes of admin‑ istration [55].”
Cited by
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.012 · Cited by 40
Desai, M. G., Kundu, A., Hageman, M. J., Lou, H., Tenjarla, S. N., Sun, C. C., Zhang, F., & Rahman, O. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01132-8 · Cited by 13
“However, newer drug delivery devices with higher volume limits, such as on-body delivery systems (OBDSs), allow for the administration of low-concentration, large-volume formulations (3, 7, 8).”
Cohen, G. L., Coetzee, C., Walton, C. A., Reig, Ò., Cho, B. C., McAdam, G. L., Rojas, C. I., Rodríguez, L. M., Pápai, Z., Chan, S. W., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115709 · Cited by 13
Szabados, B. E., Guerrero‐Ramos, F., Grande, E., Grivas, P. D., Grünwald, V., Miguel, M. C., Hussain, S. A., Kulkarni, G. S., Wilson, A. L., Shore, N. D., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00334-6 · Cited by 6
“In addition, many patients prefer SC over IV administration because of shorter treatment times and decreased discomfort [32–34 , 38].”
Franzese, C., Hawthorne, J., Katsaros, D., & Coyne, M. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s515565 · Cited by 7
“12 Similar preference for SC treatments has been observed in oncology therapeutic areas, both when IV and SC treatment options are administered in clinic 9,89 and when home administration has been explored.”
Metadata
- Authors
- Aguiar-Ibáñez, R., Fotheringham, I., Mittal, L., Sillah, A., & Pathak, S.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Advances in Therapy
- Published
- 2024-10-19
- Volume
- 41
- Issue
- 12
- Pages
- 4396-4417
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W4403566765
- Cited by
- 19
- References
- 54
- Citations by year
- 2026: 13 · 2025: 6
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Advances in Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck & Co., Inc., Rahway, NJ, USA
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Safe Handling of Antineoplastic Drugs
- Keywords
- subcutaneous administration, intravenous administration, cancer therapy, patient preferences, healthcare provider preferences, treatment duration, economic burden, health care costs, healthcare system perspective, patient-reported outcomes
- MeSH terms
- Antineoplastic Agents, Health Personnel, Humans, Injections, Subcutaneous, Neoplasms, Patient Preference, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.